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The cystic fibrosis (CF)-causing mutant, deltaF508-
CFTR, is misfolded and fails to traffic out of the endo-
plasmic reticulum (ER) to the cell surface. Introduc-
tion of second sitemutations that disrupt a diarginine
(RXR)-based ER retention motif in the first nucleotide
binding domain rescues the trafficking defect of del-
taF508-CFTR, supporting a role for these motifs in
mediating ER retention of themajormutant. To deter-
mine if these RXR motifs mediate retention of the
native deltaF508-CFTR protein in situ, we generated
peptides that mimic these motifs and should antago-
nize mistrafficking mediated via their aberrant expo-
sure. Here we show robust rescue of deltaF508-
CFTR in cell lines and in respiratory epithelial tissues
by transduction of RXRmotif-mimetics, showing that
abnormal accessibility of this motif is a key deter-
minant of mistrafficking of the major CF-causing
mutant.
INTRODUCTION
Mutations in the cystic fibrosis transmembrane conductance
regulator (CFTR) are associated with impaired chloride flux
across epithelia lining the respiratory and gastrointestinal tracts,
leading to altered epithelial fluid transport and production of
mucus plugs, the hallmark pathology associated with the devel-
opment of CF (Amaral, 2005; Cheung et al., 2008; Sheppard and
Welsh, 1999). The most common CF mutation, deletion of F508
(deltaF508-CFTR) in the first nucleotide binding domain (NBD1),
causes misfolding and misassembly of the mutant protein,
resulting in its retention in the ER and failure to be functionally
expressed at the apical surface of epithelia.
Misfolding of deltaF508-CFTR results in its altered interaction
with proteins involved in ER quality control (Younger et al., 2004,
2006). Nontargetedmaneuvers generally aimed at correcting the
folding and misassembly defects in deltaF508-CFTR, including
reduced cell culture temperatures (Denning et al., 1992) and520 Chemistry & Biology 16, 520–530, May 29, 2009 ª2009 Elsevierchemical chaperones (Pedemonte et al., 2005; Van Goor et al.,
2006), have been shown to ‘‘rescue’’ the functional expression
of the mutant protein at the cell surface. However, because
some of these chemical chaperones are known to exert off-
target effects (Wang et al., 2007), there is a clear need to design
more targeted therapeutic interventions.
Hypothetically, a targeted therapeutic intervention could
modify the function of a protein known to contribute to the reten-
tion of deltaF508-CFTR in the ER. However, there are multiple
barriers to the progression of deltaF508-CFTR to the cell
surface, and the proteins that comprise these barriers have yet
to be fully determined. As an alternative strategy, a specific inter-
vention could be developed if we understood the structural
defects inherent in deltaF508-CFTR that result in its mistraffick-
ing. Recently, there has been remarkable progress in our under-
standing of the structural defects in the major mutant (Du et al.,
2005; He et al., 2008; Serohijos et al., 2008). Intramolecular inter-
actions within this multidomain protein appear to be perturbed
by the deltaF508 mutation, possibly leading to the altered expo-
sure of trafficking signals. For example, the anterograde traf-
ficking of deltaF508-CFTR from the ER to the Golgi is thought
to be impaired because the proper presentation of a diacidic
motif in NBD1 that normally mediates interaction with Sec23/
24 of the COPII vesicular pathway is lacking (Wang et al.,
2004). To compound this defect in anterograde trafficking,
Chang and colleagues identified RXR-based ER retention/
retrieval motifs that are thought to be aberrantly exposed in the
majormutant (Chang et al., 1999; Hegedus et al., 2006).Mutation
of the four endogenous RXR-based retention motifs in the
context of deltaF508-CFTR resulted in a significant increase in
the functional expression of this mutant as a regulated chloride
channel (albeit with abnormal channel activity) at the cell surface
(Chang et al., 1999; Hegedus et al., 2006). A similar observation
was described by Amaral and colleagues (Roxo-Rosa et al.,
2006), who suggested that deltaF508-CFTR is targeted for retro-
grade trafficking back to the ER by virtue of aberrantly exposed
RXR motifs. Previously, Teem and Welsh determined that
second site revertant mutations in an endogenous RXR motif,
proximal to the ABC signature sequence in NBD1 (including
R553M and R555K in the motif: R553AR555), partially restored
trafficking of deltaF508-CFTR, suggesting that the motif in thisLtd All rights reserved
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Targeting Retention of the Major CF MutantFigure 1. Synthetic Peptides Designed to
Antagonize Retrograde Trafficking of Del-
taF508-CFTR
(A) Schematic illustrating defective anterograde
trafficking of deltaF508-CFTR to the Golgi from
the ER (stippled arrow) and enhanced retrograde
trafficking from Golgi to ER (solid arrow) (left).
Right diagram shows the hypothesis wherein
peptides containing strong ER retention motifs
(blue line) will antagonize retrograde trafficking
(blue cross) and increase cargo availability for
delivery to the plasma membrane.
(B) Micrograph (63X magnification) of a 1 micron
section through BHK cells exposed to fluoro-
phore-conjugated CPP (1 mM) for 1 hr. Alexa-
Fluor-488 (AF-488)-labeled CPPs are taken up
into vesicular structures (green in merge, far right)
from which diffusion into the cytosol occurs. The
periphery of each cell is apparent in differential
interference contrast (DIC) image (far left) and by
concanavalin A-Rhd labeling (red in merge, far
right).region has particular functional significance (Teem et al., 1993,
1996).
However, interpretation of these and the previous studies is
limited because mutation of RXR motifs in deltaF508-CFTR is
known to incur secondary alterations in the conformation of
NBD1 and in the full-length mutant protein (Hegedus et al.,
2006; Lewis et al., 2005; Pissarra et al., 2008; Teem et al.,
1996). Therefore, the role of RXRmotifs in trafficking of the native
mutant protein in situ has yet to be defined. In the current study,
we tested the role of RXRmotifs in deltaF508-CFTR trafficking by
delivering exogenous peptides bearing RXR motifs. These
peptides were conjugated to a cell-penetrating peptide module
to facilitate their intracellular delivery (Figure 1A). The relative effi-
cacy of these peptides in modifying the trafficking of the major
mutant was determined in vivo in heterologous expression
systems and in human primary respiratory epithelial cells ob-
tained fromCF patients homozygous for the deltaF508mutation.
Our observations indicate that the RXR motif proximal to the
signature sequence in NBD1 is aberrantly exposed in the major
mutant, and modification of its accessibility in situ will promote
improved surface expression of the major CF-causing mutant.
RESULTS
Transduction of a Synthetic Peptide Predicted
to Disrupt RXR-Mediated Trafficking Modifies the
Functional Expression of DeltaF508 at the Surface
of Stably Transfected Cells
A potential role for diarginine-based ER retention motifs in mis-
trafficking of deltaF508-CFTRwas revealed using amutagenesis
approach in which the consequences of disrupting each motif
were determined (Chang et al., 1999). The goal of the current
study was to determine the role for these motifs in the context
of the deltaF508-CFTR protein with its native sequence, by deliv-
ering peptides that should interfere with their function in a
specific and targeted manner. Previous studies by ZerangueChemistry & Biology 16and colleagues demonstrated that the molecular context of
RXR motifs dictates their efficiency as ER retention signals (Zer-
angue et al., 2001). Using high-throughput screening of a peptide
combinatorial library, the sequence TLRKRIR was scored as
a strong ER retention sequence whereas ENRLRLQ was scored
as a relatively weak ER retention sequence (Zerangue et al.,
2001). One would therefore predict that intracellular delivery of
the TLRKRIR peptide should be more effective than the delivery
of the ENRLRLQ peptide in antagonizing the retention of del-
taF508-CFTR mediated by exposed RXR motifs.
To enable intracellular delivery, the two synthetic peptides en-
coding the RXRmotifs described above were conjugated to cell-
penetrating peptides (CPPs) based on the Tat transduction
module (Kaplan et al., 2005). CPPs have been used extensively
to deliver peptides and larger cargo (Kaplan et al., 2005; Snyder
and Dowdy, 2004) and we confirmed by flow cytometry that flu-
orescently (AlexaFluor-488) labeled CPP-linked peptides were
effectively taken up by approximately 95% of BHK-deltaF508-
3HA cells (see Figure S1 available online). The intracellular local-
ization of the peptides was also verified by fluorescence micros-
copy (Figure 1B).
The effect of CPP-conjugated TLRKRIR (CPP-TLRKRIR) or
ENRLRLQ (CPP-ENRLRLQ) on the functional expression of del-
taF508-CFTRwasmonitored using HEK293MSR-GT cells stably
expressing deltaF508-CFTR and transfected with the halide-
sensitive mutant version of the yellow fluorescent protein (YFP-
H148Q/I152L) initially described by Pedemonte and colleagues
(Galietta et al., 2001; Pedemonte et al., 2005). An increase in
YFP quenching upon addition of NaI (52 mM) is indicative of an
increase in deltaF508-CFTR function at the cell surface. In this
previously published work, pretreatment of cells stably express-
ingdeltaF508-CFTRwithCorrector 4a for 24 hr led to a significant
increase in the functional expression of deltaF508-CFTR at the
cell surface. We reproduced this ‘‘correction,’’ which is shown
in Figure 2A. Addition of the strong ER retention sequence
CPP-TLRKRIR (1 mM) for 24 hr to HEK293MSR-GT-deltaF508, 520–530, May 29, 2009 ª2009 Elsevier Ltd All rights reserved 521
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Targeting Retention of the Major CF MutantFigure 2. Synthetic Peptides Encoding RXR
Motifs Modulate DeltaF508-CFTR Traf-
ficking
(A) Curves show quenching of yellow fluorescent
protein (YFP) after NaI addition to HEK-fibroblasts
stably expressing deltaF508-CFTR and transiently
expressing enhanced YFP. Prior to NaI addition,
mutant CFTR had been activated using a cocktail
of cAMP agonists plus genistein. Cells were pre-
treated with CPP-conjugated RXR peptides, the
corrector 4a compound, or vehicle alone (control)
for 24 hr.
(B) Bars show mean YFP quenching in wells
exposed to peptides or Corrector 4a relative to
control (vehicle treated) (n = 7). CPP-TLRKRIR
(1mM)and1mMcorrector 4asignificantly increased
YFP quenching at 36 s by 7.3 ± 1.2% (*p < 0.05)
and 10.6 ± 1.4% (***p < 0.001), respectively.
Mean±SEMareshown,andstatistical significance
was assessed using ANOVA and a secondary
Bonferroni test of certain data set pairs.
(C) Analysis of surface expression of deltaF508-
CFTR bearing exofacial 3HA tag by flow cytome-
try. A representative histogram of cells treated
with CPP-TLRKRIR (blue), CPP-ENRLRLQ (red)
versus untreated BHK-deltaF508-3HA cells
(shaded gray).
(D) Bars show mean change in surface expression
in multiple studies (n = 5). CPP-TLRKRIR [1 mM]
significantly increases relative cell surface expres-
sion 1.8 ± 0.1-fold (***p < 0.001). Mean ± SEM are
shown, statistical significance assessed using
ANOVA and a secondary Bonferroni test of certain
data set pairs.cells transfected with the mutant YFP also led to a significant
(7.3 ± 1.2%) increase in the rate of YFP quenching (*p < 0.05),
whereas the weak ER retention sequence CPP-ENRLRLQ failed
to elicit a significant response (Figures 2A and 2B). The differen-
tial effect of CPP-TLRKRIR and CPP-ENRLRLQ peptides
supports the utility of this transduction system to specifically
target known protein interaction motifs and suggests that antag-
onism of the interaction between deltaF508-CFTR and the ER
retention machinery modulates the trafficking of the major
mutant. Interestingly, the success of the CPP-TLRKRIR in
promoting functional rescue of deltaF508-CFTR was compa-
rable to that of Corrector 4a (1 mM), a compound previously
shown to be an effective corrector in this assay (Pedemonte
et al., 2005) (Figure 2B).
In order to determine directly if the trend for increased func-
tional expression following treatment with peptides bearing the
strong retention motif reflected an absolute increase in del-
taF508-CFTR trafficking to the surface, we studied cells stably
expressing deltaF508-CFTR bearing an exofacial triple-HA tag
(Du et al., 2005) by flow cytometry. The total deltaF508-CFTR
protein trafficking to the cell surface was assessed after treat-
ment with vehicle alone (control), or with CPP bearing the weak
ER retention motif (1 mM) or the strong ER retention motif
(1 mM), as detected using anti-HA antibody and secondary anti-
body conjugated with AlexaFluor-647 (AF-647). Treatment of
cells with CPP-TLRKRIR (1 mM, blue line) increased the relative
cell surface expression of deltaF508-CFTR by 1.8 ± 0.1-fold
(***p < 0.001), whereas CPP-ENRLRLQ (1 mM, red line) caused522 Chemistry & Biology 16, 520–530, May 29, 2009 ª2009 Elseviernosignificant increase in surfaceexpressionof themutant protein
relative to control samples (shadedgray) (Figures2Cand2D). The
results of this direct assay of surface expression support the find-
ings of the YFP quenching assay, and show that there is a differ-
ential effect of the ‘‘weak’’ and ‘‘strong’’ motif-mimetic peptides
on trafficking of deltaF508-CFTR, consistent with their predicted
efficacies in competing ER retention mechanisms.
Transduction of a Peptide Containing Endogenous RXR
Motif Proximal to the ABC Signature Motif of NBD1
(CF-RXR) Increases DeltaF508-CFTR Function by
Promoting Cell Surface Trafficking
We then asked if delivery of a synthetic peptide bearing an RXR
motif endogenous in the CFTR protein and previously implicated
in ER retrieval of deltaF508-CFTR (Chang et al., 1999; Hegedus
et al., 2006; Teem et al., 1993, 1996) was also effective in modu-
lating trafficking of the mutant protein. The current studies focus
on the RXR motif residing in NBD1, proximal to the ABC signa-
ture motif and starting at the arginine at position 553, as it has
been implicated in ER retrieval of deltaF508-CFTR with muta-
tions R553M/Q or R555K leading to the enhanced surface
expression of the major mutant (Teem et al., 1993, 1996). We
therefore predict that transduction of a peptide containing this
CF-specific RXR motif (GGQRARISLARAVYK) should effectively
antagonize the retention of deltaF508-CFTR if this region is aber-
rantly exposed in the mutant protein.
To assess deltaF508-CFTR trafficking and function in the
presence of CPP-conjugated CF-RXR (CPP-CF-RXR), weLtd All rights reserved
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Targeting Retention of the Major CF Mutantperformed both the YFP quenching assay and flow cytometry
assays as described earlier for assessment of CPP-TLRKRIR
and CPP-ENRLRLQ. In Figures 3A and 3B, we show that delivery
of the CPP-CF-RXR (1 mM) induced a significant 10.7 ± 1.7%
(C***p < 0.001) increase in the functional expression of del-
taF508-CFTR (detected as YFP quenching), an increase compa-
rable to that evoked by the Corrector 4a (1 mM), (10.6 ± 1.4%). In
contrast, cells treated with CPP alone showed no significant
increase in YFP quenching relative to untreated samples.
Although the magnitude of quenching cannot be directly corre-
lated with halide flux because there is a nonlinear relationship
between these two parameters (Galietta et al., 2001), the CPP-
CF-RXR peptide is clearly effective in promoting the functional
expression of deltaF508-CFTR.
The change in functional expression of deltaF508-CFTR
evoked by CPP-CF-RXR treatment was associated with its
enhanced localization at the surface because there was
Figure 3. CPP-CF-RXR Enhances Del-
taF508-CFTR Trafficking
(A) Representative trace of YFP quenching de-
tected in cells treated with CPP, CPP-CF-RXR,
and corrector 4a relative to control (vehicle-
treated) cells.
(B) Bars showmean YFP quenching (±SEM, n = 8).
CPP-CF-RXR (1 mM) and 1 mM corrector 4a signif-
icantly increased YFP quenching at 36 s by 10.7 ±
1.7% (***p < 0.001) and 10.6 ± 1.4% (***p < 0.001),
respectively. Statistics were processed using
ANOVA and a secondary Bonferroni test of certain
data set pairs.
(C) Representative histograms of cells expressing
deltaF508-CFTR-3HA at the cell surface, as de-
tected using anti-HA monoclonal and Alexa-647-
labeled anti-mouse secondary antibody following
pretreatment with CPP-CF-RXR (blue), CPP
(red), or untreated BHK-deltaF508-3HA cells
(shaded gray) as analyzed by flow cytometry.
(D) Bars show mean ± SEM (change in surface
expression following different peptide treatments
in multiple experiments [n = 8] relative to control).
CPP-CF-RXR (1 mM) significantly increased rela-
tive cell surface expression 10.0 ± 2.4-fold (**p <
0.01). Statistics were processed using ANOVA
and a secondary Bonferroni test of certain data
set pairs.
(E) Concentration-dependent effects of CPP-CF-
RXR exhibit saturation (blue, single site binding
algorithm, EC50 = 0.48 mM, r
2 = 0.94). The carrier
(CPP, red) alone does not increase surface
expression of deltaF508-CTFR relative to control
(no treatment).
increased presentation of its exofacial
3HA tag in deltaF508-CFTR as detected
by an anti-HA antibody and a fluorescent
secondary antibody by flow cytometry.
Addition of CPP-CF-RXR (1 mM, blue)
for 3 hr induced a significant increase in
deltaF508-CFTR cell surface expression
by 10.0 ± 2.4-fold (*p < 0.01) relative to
CPP-treated (red) or untreated (shaded gray) cells (Figures 3C
and 3D). The ability of the CPP-CF-RXR peptide to increase
the cell surface expression of deltaF508-CFTR-3HA (as deter-
mined by flow cytometry) exhibits a saturable concentration
dependence with an estimated EC50 of 0.48 mM peptide
(Figure 3E).
In order to compare the level of correction in the functional
expression of deltaF508-CFTR mediated by the synthetic CPP-
CF-RXR peptide to the functional expression of the wild-type
CFTR protein, we compared two BHK cell lines: one stably
expressing the major mutant and the other, wild-type CFTR.
Treatment of BHK cells expressing the mutant protein with
CPP-CF-RXR peptide (1 mM) for 1.5 hr led to a significant 2.9 ±
0.5-fold (**p < 0.01) increase in the rate of normalized halide
transport relative to untreated samples (Figures 4A and 4B),
and represents approximately 30% of the cyclic-AMP activated
iodide efflux measured for wild-type CFTR expressed in theChemistry & Biology 16, 520–530, May 29, 2009 ª2009 Elsevier Ltd All rights reserved 523
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Targeting Retention of the Major CF MutantFigure 4. CPP-CF-RXR Enhances Func-
tional Expression of DeltaF508-CFTR to
30% Levels of Normal CFTR and Enhances
N-Glycan Processing
(A) Representative iodide efflux response to cAMP
stimulation cocktail of BHK cells expressing wild-
type CFTR or deltaF508-CFTR (DF508) (mean ±
SEM of triplicate experiments). Agonist cocktail
induces peak in the rate of iodide efflux from cells
expressing wild-type CFTR but not deltaF508-
CFTR unless pretreated with 1 mM CPP-CF-RXR
for 1.5 hr (or 3 hr: 224 ± 79 nmol/min).
(B) Bars show mean ± SEM peak iodide efflux
rates in multiple comparative experiments of del-
taF508-CFTR (n = 4), or wild-type CFTR (n = 4).
Efflux rates normalized relative to control rates
determined for cells expressing deltaF508-
CFTR. CPP-CF-RXR (1 mM) significantly enhances
cAMP-dependent deltaF508-CFTR function by
2.9 ± 0.5-fold (**p < 0.01, paired t test) over
untreated (control) cells, to achieve approximately
30% of the cAMP response exhibited by wild-type
CFTR in a distinct set of studies (9 ± 2.5-fold over
control).
(C) Bars show lack of effect of 1 mM CPP-CF-RXR
peptide on functional expression of wild-type
CFTR where efflux rates are normalized relative
to control values in untreated cultures expressing
wild-type CFTR (n = 7, paired t test).
(D) Western analysis of deltaF508-CFTR matura-
tion. DeltaF508-CFTR protein migrates primarily
as core glycosylated 150 kDa protein (band B,
solid triangle), and wild-type CFTR migrates
primarily as complex glycosylated 170-180 kDa
protein (band C, open triangle). CPP-CF-RXR
(10 mM) for 3 hr at 37C stabilizes band B (closed
arrow) and increases maturation of band C (open
arrow).
(E) Quantification of band B and band C in multiple
studies (n = 4). Mean ± SEM are shown. Statistical
significance was assessed using an unpaired t test
(*p < 0.05).
(F) Top panel shows conversion of 35S-methionine
pulse-labeled precursor form of wild-type CFTR (band B, solid triangle, time 0 hr) to mature form (band C, empty triangle) after chase times shown. Cells were
starved of methionine, pulsed for 15 min with 35S-methionine + 35S-cysteine labeling mix (150 mCi/ml), and chased for 0, 1, 2, or 3 hr in methionine-containing
medium. Middle panel shows failure of conversion for deltaF508-CFTR. Lower panel shows partial conversion for deltaF508-CFTR following a 2 hr pretreatment
with CPP-CF-RXR (10 mM, as final concentration) at 37C followed by subsequent treatment with 1 mMCPP-CF-RXR in the chasemedia. This protocol was devel-
oped tomaintain total peptide exposure during the entire pulse-chase experiment at levels comparable to biochemical experiments shown in (d). Control samples
(pretreatment with a similar volume of the peptide vehicle, PBS) were not significantly different than deltaF508-CFTR untreated (data not shown).
(G) Biosynthetic maturation efficiency for different chase times was determined as the intensity of 35S-methionine incorporated band C relative to the total
amount of 35S-methionine band B precursor at time 0 hr. Symbols show mean data (±SEM) from deltaF508-CFTR (gray triangles, three independent trials)
and CPP-CF-RXR-pretreated deltaF508-CFTR (inverted blue triangles, three independent trials). At 3 hr of chase, there is a significant difference in maturation
efficiency resulting from peptide pretreatment (unpaired t test, p < 0.01). Black squares show mean maturation efficiency of wild-type CFTR over time for two
independent trials.same cell type. We also investigated the effect of treating del-
taF508-CFTR with CPP-CF-RXR for 3 hr (so as to be consistent
with flow cytometry assays) and found that the efflux measured
was similar to that produced from a 1.5 hr peptide treatment
(data not shown). The delay in the peak iodide efflux of the
CPP-CF-RXR-treated deltaF508-CFTR-expressing cells relative
to the peak observed in cells expressing wild-type CFTR has
been observed for pharmacological correctors and likely reflects
the defect in gating kinetics exhibited by the mutant protein
(Clarke et al., 2004; Sheppard et al., 1993). In Figure 4C, we
show that treatment of cells expressing wild-type CFTR with524 Chemistry & Biology 16, 520–530, May 29, 2009 ª2009 ElsevierCPP-CF-RXR (n = 7) fails to promote a significant increase in
the relative functional expression of CFTR at the cell surface rela-
tive to control (n = 7). These findings suggest that this peptide is
targeting a molecular recognition site that is aberrantly exposed
in the mutant, deltaF508-CFTR.
DeltaF508-CFTR migrates primarily as a 140–150 kDa protein
(band B) when analyzed by SDS-PAGE, whereas the normal
protein migrates primarily as a 170–180 kDa protein (band C).
The differential migration of themutant protein reflects its relative
retention in the ER and failure to traffic to the Golgi where
complex glycosylation is conferred to generate the matureLtd All rights reserved
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Targeting Retention of the Major CF MutantFigure 5. Functional Rescue of DeltaF508-
CFTR by CF-RXR Is Sequence Specific and
Mediated by Interfering with Endogenous
RXR
(A) Bars show mean cAMP-dependent activation
in BHK cells expressing deltaF508-CFTR with
(+, n = 4) or without (, n = 4) peptide (ppt)
pretreatment for 1.5 hr. Data obtained using the
CF-derived peptide bearing the endogenous
motif and coupled to the carrier (CPP): CF-RXR
is shown for comparison [2.9 ± 2.5-fold over
control (*p < 0.01)] with the mutated CF-derived
peptide wherein arginines are replaced with
lysines: CF-KXK. No statistically significant
change was stimulated by the mutant peptide.
Mean ± SEM are shown. A paired t test was
used to perform statistical analysis.
(B) BHK-deltaF508-3HA cells failed to show
enhanced surface expression after treatment
with CPP-coupled CF-KXK peptides (dark gray)
relative to untreated cells (shaded gray), as deter-
mined using flow cytometry.
(C) Bars show cAMP-activated iodide efflux
by deltaF508-CFTR protein bearing a mutant
R553XR555 wherein arginine residues are mutated
to KXK (DFRK). Treatment of cells expressing
DFRK with CF-RXR peptide (ppt, n = 3) caused
no additional cAMP response (paired t test).
(D) Western blotting of deltaF-CFTR (DF), wild-
type CFTR, and deltaF-CFTR with mutation of
R553XR555 to KXK (DFRK) shows partial correction of processing defect of deltaF508-CFTR caused by genetic modification of RXRwith increase in band C gener-
ation (open triangle). As expected for effect mediated by R553XR555, the CF-RXR peptide (+, 10 mM) fails to cause an additive effect on band C (open triangle)
generation in cells expressing deltaF508-CFTR (KXK) (right panel).form of the protein. We reasoned that if CPP-CF-RXR is acting to
modulate trafficking of deltaF508-CFTR by antagonizing its ER
retention, we would detect enhancedGolgi-dependent glycosyl-
ation. As shown in Figures 4D and 4E, treatment of BHK-del-
taF508-3HA with CPP-CF-RXR (10 mM) for 3 hr at 37C led to
a significant 1.8 ± 0.4-fold (*p < 0.05) enhancement in the
appearance of complex glycosylated band C (open arrow). Inter-
estingly, treatment of cells with CPP-CF-RXR peptide at the
lower concentration of 1 mM, the concentration that is effective
in promoting functional cell surface expression as detected by
flow cytometry and halide flux assays, does not consistently
lead to the enhanced appearance of band C. Rather, the require-
ment for the higher concentration of 10 mMpeptide suggests that
this biochemical assay is less sensitive than functional analyses
or flow cytometry in detecting surface expression of the major
mutant. The relative insensitivity of western blotting and detec-
tion of band C production relative to direct measures of surface
expression (similar to the flow cytometry assay) has been
observed previously (Pedemonte et al., 2005).
We performed kinetic pulse-chase experiments to directly test
our hypothesis that the CPP-CF-RXR peptide promotes forward
trafficking of newly synthesized deltaF508-CFTR to the Golgi.
First, we confirmed previous studies showing that the trafficking
of newly synthesized deltaF508-CFTR protein from the ER to the
Golgi (conversion from the band B to band C form of the protein)
is impaired relative to the wild-type CFTR protein (Figures 4F and
4G). As in previous publications by Riordan and colleagues
(Chang et al., 1999), we found no conversion to band C for del-
taF508-CFTR over the 3 hr chase period of 35S-methionineChemistry & Biology 16labeled protein. However, 30%–40% of wild-type CFTR protein
undergoes conversion during this time. These values are consis-
tent with several publications (Chang et al., 1999; Pedemonte
et al., 2005; Van Goor et al., 2006). Treatment of deltaF508-
CFTR-expressing cells with CPP-CF-RXR (10 mM) at 37C led
to a modest (15%) but significant increase in conversion of
band B to band C in three independent trials. This result is
consistent with studies by Riordan and colleagues (Chang
et al., 1999) wherein mutagenesis of intrinsic RXR-based reten-
tion motifs led to a 10% increase in maturation efficacy of del-
taF508-CFTR. Therefore, these kinetic data support the hypoth-
esis that the CPP-CF-RXR peptide modulates the trafficking of
deltaF508-CFTR through the biosynthetic pathway.
Next, we were prompted to determine if this peptide is acting
to correct mistrafficking of deltaF508-CFTR by interfering with
ER retention mediated by the endogenous R553XR555 motif in
deltaF508-CFTR. First, we synthesized a mutant peptide,
wherein the arginineswere replaced by lysines (CF-KXK). Substi-
tution of one of the two arginines in the motif was previously
shown to inactivate this retention motif (Chang et al., 1999;
Hegedus et al., 2006; Teem et al., 1996). In Figure 5A, we
show that 1 mM CF-KXK (GGQKAKISLARAVYK conjugated to
the same CPP as the CF-RXR peptide) was ineffective in causing
rescue of the functional expression of deltaF508-CFTR, in
contrast to the previous results obtained for CF-RXR. Further-
more, we found that CF-KXK (1 mM) also failed to cause an
increase in the surface expression of deltaF508-CFTR bearing
an exofacial triple-HA tag (Figure 5B). To further probe the
specific activity of the exogenous CF-RXR peptide on function, 520–530, May 29, 2009 ª2009 Elsevier Ltd All rights reserved 525
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Targeting Retention of the Major CF Mutantof the endogenous R553XR555 motif in deltaF508-CFTR, we con-
structed a deltaF508(RK)-CFTR mutant, whereby the arginines
at position R553 and R555 were mutated to lysines. We predict
that if our CPP-CF-RXR peptide is specifically mediating rescue
of deltaF508-CFTR by interfering with interactions occurring
between aberrantly exposed RXR motifs and the ER retention
machinery, then the CPP-CF-RXR peptide should exert no effect
on deltaF508(RK)-CFTR. As expected on the basis of previous
studies (Teem et al., 1993, 1996), we found that deltaF508(RK)-
CFTR exhibits partial maturation to the complex glycosylated
form of the protein (Figure 5D). Furthermore, fraction of del-
taF508(RK) at the surface is at least partially functional because
it mediates greater cAMP-dependent halide flux than deltaF508-
CFTR (as determined using the iodide efflux assay, and analyzed
by unpaired t test, **p < 0.01). Interestingly, the rate of iodide
efflux mediated by the deltaF508(RK)-CFTR mutant was similar
to that observed for deltaF508-CFTR treated with CPP-CF-
RXR peptide (Figures 5A and 5C, unpaired t test). Importantly,
treatment of the deltaF508(RK)-CFTR mutant construct with
CPP-CF-RXR peptide (1 mM) for 1.5 hr failed to increase the
rate of cAMP-dependent iodide efflux over the untreated sample
(Figure 5C). Furthermore, even relatively high concentrations of
the CPP-CF-RXR peptide (10 mM) did not cause an increase in
deltaF508(RK)-CFTR processing to the band C form of the
protein (Figure 5D, right panel), in contrast to its effect on the
native deltaF508-CFTR sequence (Figure 4D). Together, these
studies support our claim that the cellular delivery of CPP-CF-
RXR causes partial correction of the trafficking defect of del-
taF508-CFTR by antagonizing the effects of this motif.
Because certain pharmacological small-molecule modulators
exhibit dual activity and rescue the trafficking defect of del-
taF508-CFTR as well as directly enhance or potentiate channel
activity (Loo et al., 2006), we were prompted to assess the
activity of the CPP-CF-RXR peptide as a potentiator. For these
studies, BHK cells stably expressing deltaF508-CFTR were first
subjected to biosynthetic rescue by incubation at 27C for 24 hr,
and the effect of the addition of CPP-CF-RXR (1 mM) on surface-
expressed and cAMP-activated deltaF508-CFTR protein was
assessed using the iodide efflux assay. We found that the rate
of halide (iodide) efflux was not significantly altered by 1 mM
CPP-CF-RXR treatment: efflux rate 180 ± 42 (standard error of
the mean [SEM]) nmol/min (n = 3) versus 120 ± 18 (SEM) nmol/
min (n = 3) (p = 0.28, unpaired t test) for control samples. There-
fore, these findings suggest that CPP-CF-RXR is not acting as
a potentiator, but rather it rescues functional expression through
its effect on trafficking.
CPPTransductionMediates Epithelial Uptake of Peptide
Cargo and the CF-RXR Peptide Partially Rescues the
Functional Expression of DeltaF508-CFTR Expressed
in Human Bronchial Epithelial Cell Monolayers
Weproceeded to investigate the consequences of peptide treat-
ment in primary cultures of human bronchial epithelia obtained
from patients homozygous for the deltaF508 mutation. These
cells were grown and maintained in the presence of an air-liquid
interface on collagen coated inserts to form polarized and fully
differentiated monolayers (Farmen et al., 2005). Because
multiple monolayers were generated from a single patient, the
consequences of peptide treatment could be determined526 Chemistry & Biology 16, 520–530, May 29, 2009 ª2009 Elsevierrelative to control (vehicle-alone) treatments for each patient in
a pairwise fashion, thereby eliminating the influence of patient-
to-patient variability. These inserts were treated with 1 mM
CPP-CF-RXR on both apical and basolateral sides for 3 hr
(control samples were treatedwith a similar volume of the vehicle
for peptide). The inserts were mounted into Ussing chambers
and studied in the presence of physiological chloride solutions
under voltage clamp conditions. ENaC currents were inhibited
using 100 mM amiloride and non-CFTR chloride channels were
inhibited with 250 mM 4,40-dinitrostilbene-2,20-disulfonic acid
(DNDS). CFTR-associated chloride currents were stimulated
with 20 mM forskolin and 500 mM 3-isobutyl-1-methylxanthine
(IBMX) and inhibited using 5 mM CFTR-inh172, a specific CFTR
inhibitor (Ostedgaard et al., 2002; Pedemonte et al., 2005; Van
Goor et al., 2006) (Figure 6B). We examined a total of nine mono-
layers from three different patients. As previously mentioned, the
studies were performed in a paired fashion so that the effect of
peptide treatment was compared with vehicle alone on mono-
layers obtained from the same patient. As shown in Figure 6C,
monolayers treated with 1 mM CPP-CF-RXR for 3 hr displayed
an almost 2-fold (*p < 0.05) increase in the forskolin and IBMX
Figure 6. CPP-CF-RXR Partially Rescues Functional Expression of
DeltaF508-CFTR in Airway Epithelia
(A) Representative short circuit current traces on bronchial epithelial mono-
layers obtained from non-CF control patients. Both apical and basolateral
epithelial surfaces exposed to physiological salt solutions (containing
137 mM NaCl) with endogenous ENaC currents inhibited by amiloride
(100 mM) in the apical compartment. CFTR currents were activated by 20 mM
forskolin and 500 mM IBMX. Activated currents are inhibited by the CFTR-
specific inhibitor CFTRinh-172 (5 mM).
(B) Representative traces of currents mediated by monolayer of primary bron-
chial epithelial cells generated from tissue obtained from a patient homozy-
gous for the deltaF508-CFTR mutation, treated with vehicle alone or CPP-
CF-RXR (1 mM) for 3 hr. DeltaF508-CFTR currents in peptide treated epithelium
are activated by agonists of cAMP and inhibited by inhibitor CFTRinh-172.
(C) Bars show mean ± SEM short circuit current responses to cAMP agonists
in paired studies of vehicle or peptide (CPP-CF-RXR) treated bronchial mono-
layers derived from CF patients bearing the deltaF508-CFTR mutation (n = 9
pairs). CPP-CF-RXR (1 mM) significantly increased forskolin and IBMX
response 2-fold (*p < 0.05) relative to untreated monolayers. Statistical anal-
ysis was performed using a paired t test. Solid line above bars shows the
mean cAMP-dependent response by non-CF monolayers, with the gray
rectangle representing the SEM (n = 8).Ltd All rights reserved
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Targeting Retention of the Major CF Mutantresponse (1.6 ± 0.4 mA/cm2) relative to non-peptide-treated
controls (0.8 ± 0.3 mA/cm2). The results from comparative
studies using monolayers obtained from subjects with normal
CFTR are also shown in Figures 6A and 6C. On the basis of these
comparative studies, we estimate that the CPP-CF-RXR-treated
deltaF508-CFTR monolayers have approximately 30%–40% of
normal CFTR chloride channel activity. These findings suggest
that the CPP is taken up by epithelial tissues, and further that
the cell surface expression of deltaF508-CFTR can be modu-
lated specifically in human respiratory epithelial cells by deliv-
ering a peptide designed to antagonize a specific recognition
motif for ER retention.
DISCUSSION
Much of our current understanding of themolecular mechanisms
that underlie mistrafficking of the major CF-causing mutant del-
taF508-CFTR has been developed through genetic manipulation
of protein components in the biosynthetic compartment and/or
mutagenesis of the deltaF508-CFTR itself. However, mutational
analyses of ER trafficking motifs might introduce changes in the
deltaF508-CFTR protein in addition to the intended disruption of
a trafficking event. Because second-site mutations introduced in
the context of deltaF508-CFTR protein might induce conforma-
tional changes (Pissarra et al., 2008), it is important to verify that
the mechanisms identified in the previous studies are functional
for the native deltaF508-CFTR protein (without second site
mutations) in their appropriate cell and tissue context. Such
studies require the intracellular delivery of targeted probes. We
show here that peptides designed to mimic RXR ER retention
motifs in a suitable sequence specific context, and delivered
intracellularly via a cell penetrating transduction module, can
function as such targeted probes. These peptides modified traf-
ficking of deltaF508-CFTR in a sequence-specific manner.
Furthermore, our observations allow us to conclude that RXR-
based ER retention motifs are aberrantly exposed in the
disease-causing mutant, bearing the single deletion mutation
of phenylalanine 508. Interestingly, the RXR motif proximal to
the signature motif of NBD1 of the major mutant plays a key
role as a recognition element leading to its ER retention.
We conclude that the motif mimetic peptide described in this
study, CF-RXR, caused an increase in the functional expression
of deltaF508-CFTR by interfering with its retention in the ER. This
conclusion is based on several observations. First, the treatment
of cell lines stably expressing the mutant protein with the CF-
RXR peptide enhanced the maturation efficiency of deltaF508-
CFTR as assessed in kinetic pulse chase experiments and in
studies of steady-state band C expression. An increase in its
expression as a regulated chloride channel at the cell surface
was also observed within this time frame in primary airway
epithelial monolayers from patients homozygous for this muta-
tion. Furthermore, removal of the endogenous ER retention motif
(R553XR555) in cis with deltaF508-CFTR abolished the effect of
the motif mimetic peptide on Golgi modification, surface expres-
sion, and function at the cell surface in the heterologous expres-
sion system mentioned above. Our halide efflux studies using
temperature-corrected deltaF508-CFTR showed that these
peptides did not act as potentiators of the channel activity of
deltaF508-CFTR protein. Together, these findings suggest thatChemistry & Biology 16the CF-RXR peptide partially rescued the mistrafficking of del-
taF508-CFTR.
The molecular basis for the exceptional effect of the CFTR-
derived peptide (CF-RXR) relative to the strong hypothetical
ER retention signal peptide identified from a combinatorial library
by high-throughput screen (TLRKRIR) (Zerangue et al., 2001)
remains to be fully elucidated. Our findings indicate that this
motif might be aberrantly exposed in the mutant protein and
plays a key role in ER retention. Thus, in the context of the full-
length wild-type CFTR protein, the R553AR555 motif on NBD1
likely contributes to intramolecular interactions between NBD1
andNBD2 orMSD2 (He et al., 2008;Mense et al., 2006; Serohijos
et al., 2008; Vergani et al., 2005). However, with full-length del-
taF508-CFTR protein, our findings suggest that this particular
motif is exposed, consistent with recent biochemical data
showing that normal intramolecular interactions are perturbed
in the major mutant (Du et al., 2005; Loo et al., 2008; Serohijos
et al., 2008). Interestingly, although protein fragments corre-
sponding to NBD1 of CFTR alone are known to be susceptible
to aggregation, the introduction of so-called solubilizing muta-
tions in this domain helps to prevent this process. Both arginines
at positions 553 and 555 are mutated to enhance solubility of the
human NBD1 protein fragment (Lewis et al., 2005). These obser-
vations suggest that, if exposed, the arginine residues in these
positions might be predisposed to promote non-native protein-
protein interactions.
With respect to the molecular basis for ER retention via retro-
grade trafficking of deltaF508-CFTR, the COPI coatomer protein
complex has been implicated in retrograde trafficking of the
limited number of previously studied cargo proteins, including
the misassembled ATP-sensitive K+ channel (Zerangue et al.,
1999), GABAB receptor (Margeta-Mitrovic et al., 2000), NMDA
receptor (Scott et al., 2001; Standley et al., 2000), ROMKchannel
(Yoo et al., 2005), and the Kainate receptor (Jaskolski et al.,
2004). An interaction between the b-COP subunit and del-
taF508-CFTR was determined in a heterologous expression
system following chemical crosslinking and analysis by mass
spectrometry (Wang et al., 2006). Small interfering RNA-medi-
ated knockdown of certain components of the COPI pathway
was shown to affect anterograde trafficking of CFTR (Rennolds
et al., 2008; Szul et al., 2007). These overall findings suggest
that the COPI complexmight not have a primary role inmediating
retrograde transport of deltaF508-CFTR or that particular coat-
omer subunits, not as yet studied, contribute to this function.
Therefore, identification of the interaction partner (or partners)
for the aberrantly exposed RXR motif in NBD1 that mediates
ER retention remains a priority for future study.
A further dimension to the present work is our demonstration
of the feasibility of delivering specific cargo into CF-affected
epithelia using a cell-penetrating-based peptide transduction
domain (CPP). The efficacy of this delivery module has been
documented extensively, not only for a wide range of cargo
types (DNA, RNA, and protein), but also in various tissues in
in vitro and in vivo experiments (Duchardt et al., 2007; Henriques
et al., 2006; Kaplan et al., 2005; Potocky et al., 2003; Snyder and
Dowdy, 2004; Wadia et al., 2004). A wide variety of diseases are
effectively treated in mouse models using CPP-protein
conjugates. For example, TAT-survivin, which competes or
antagonizes the interaction between Hsp90 and the survivin, 520–530, May 29, 2009 ª2009 Elsevier Ltd All rights reserved 527
Chemistry & Biology
Targeting Retention of the Major CF Mutantprotein and causes apoptosis when taken up by tumor cells,
shows promise in the treatment of prostate, breast, leukemia,
melanoma, and glioma in mice (Ma et al., 2006). The present
studies, together with a recent publication by Frizzell and
colleagues (Sun et al., 2008), suggest that peptide or protein
transduction might provide a useful strategy for targeting aber-
rant intermolecular interactions with deltaF508-CFTR. Further-
more, although the peptide employed in the current study
requires optimization for efficacy and bioavailability, it might
provide the template for designing correctors of defective del-
taF508 trafficking. Interestingly, a CPP-conjugated dPKC inhib-
itor peptide completed phase 2 clinical studies for the treatment
of a distinct clinical condition, acute myocardial infarction, with
promising results (Bates et al., 2008). There is, accordingly,
significant promise for the potential application of this approach
in therapy development.
SIGNIFICANCE
Themajor CF-causingmutation, deletion of phenylalanine in
position 508, leads to misfolding, misassembly and mistraf-
ficking of the CFTR protein with its retention in the ER.
Despite these defects, mistrafficking of the protein can be
partially corrected by variousmanipulations, including treat-
ment with chemical chaperones, and its function detected
on the cell surface. These findings suggest that effective
pharmacological treatment of patients bearing thismutation
might be feasible. Ideally, interventions that promote proper
trafficking of deltaF508-CFTR could be developed if the
structural features that confer ER retention are defined.
Prior to this current study, such features have typically
been probed by mutagenesis that might cause secondary
conformational changes not normally existing in the mutant
protein in situ. In this paper, we introduce a novel peptide-
based approach that targets an ER retention motif that
ostensibly becomes aberrantly exposed in the deltaF508-
CFTR protein. The results of the current study support the
role for diarginine motifs—in particular a diarginine motif
proximal to the signature motif in NBD1—in conferring
a molecular recognition element that contributes to mistraf-
ficking of the major mutant in situ. This structural feature
might thus comprise amolecular target for effective CF ther-
apies.
EXPERIMENTAL PROCEDURES
Cell Lines and Synthetic Peptides
Baby hamster kidney (BHK) cells stably expressing deltaF508-CFTR bearing
an exofacial triple-HA tag (BHK-deltaF508-3HA) or wild-type CFTR bearing
the exofacial triple HA tag (BHK-CFTR-3HA) obtained from Dr. G.L. Lukacs
weremaintained as described (Pedemonte et al., 2005). Griptite 293MSR cells
stably expressing deltaF508-CFTR (293MSR-GT-deltaF508) obtained fromDr.
D. Rotin were maintained in Dulbecco’s modified Eagle’s medium (DMEM)
media (MultiCell) with 10% fetal bovine serum (FBS) (Wisent), 0.1 mM NEAA
(Invitrogen), 600 mg/ml Geneticin (Invitrogen), and 5 mg/ml Blasticidin (Invitro-
gen). Human bronchial epithelia cells from transplant patients homozygous
for the deltaF508-CFTR mutation (provided by Drs. P. Karp and J. Zabner,
manager and director, respectively, of the Iowa Cell Culture Facility) were
maintained as described (Zabner et al., 1996; Zhang et al., 2004). Del-
taF508(R553/555K) construct was synthesized via site-directed mutagenesis.528 Chemistry & Biology 16, 520–530, May 29, 2009 ª2009 ElsevierPeptides were synthesized by Dr. N.C. Wang (Advance Protein Technology
Centre, Hospital for Sick Children, Toronto). Peptides were conjugated to the
CPP TAT derived from HIV1 (Kaplan et al., 2005) to facilitate intracellular
delivery (Kaplan et al., 2005; Snyder and Dowdy, 2004).
Halide Flux Assays
YFP Quenching Assay
Briefly, HEK293MSR-GT-deltaF508 cells were seeded (65,000 cells per well)
and transfected with 250 ng YFP-H148Q/I152L (Galietta et al., 2001; Pede-
monte et al., 2005) 48 hr before measurement. Cells were treated with 1 mM
peptides at 24 hr, and surface channels were stimulated with 25 mM forskolin,
10 mg/ml IBMX, and 50 mM genistein (all chemicals purchased from Sigma).
The rate of YFP quenching in the presence of NaI at a final concentration of
52 mM was acquired using Cellomics KineticScan HCS reader (SIDNET
Facility, Research Institute, Hospital for Sick Children). The development of
this assay is described elsewhere by Verkman and colleagues (Galietta
et al., 2001; Pedemonte et al., 2005) and by Trzcinska-Daneluti et al. (2009).
Kinetic analysis was performed using Python analysis software. Analysis of
variance (ANOVA) statistical analysis of cumulative quenching results was per-
formed using GraphPad Prism software.
Iodide Efflux Studies
Experiments performed as previously described (Du et al., 2005) using BHK-
CFTR-3HA or BHK-deltaF508-3HA cells in the presence or absence of peptide
[1 mM] for 1.5 or 3.0 hr. Intracellular cAMP levels were raised using 10 mM for-
skolin, 1000 mM IBMX, and 100 mM cpt cAMP (all compounds purchased from
Sigma) in order to stimulate CFTR activity. An iodide sensitive electrode was
used to measure efflux and delta response was calculated as the maximum
iodide response after stimulation minus the response before stimulation.
Statistics were processed using Prism 4 (GraphPad Software), and an
unpaired t test was used to determine significance of treated samples.
Ussing Chamber Studies
Primary human bronchial epithelial cells homozygous for deltaF508-CFTRwere
provided by the Iowa Cell Culture Facility. Epithelia were cultured on collagen
coated membrane permeable inserts as previously described (Zabner et al.,
1996). Monolayers were treated (apical and basolateral) with 1 mM peptide for
3 hr at 37C. Inserts weremounted in an Ussing chamber apparatus (PlexiCraft,
IowaCity) andstudiedundervoltageclamp (Physiologic Instruments) conditions
as previously described (Ostedgaard et al., 2002; Zabner et al., 1996). The
bathing solution, which was added to both apical and basolateral sides, con-
tained5.4mMKCl, 0.3mMNa2HPO4$7H2O, 0.4mMKH2PO4, 4.2mMNaHCO3,
137 mM NaCl, 5.6 mM D-glucose, 1.8 g/l sodium bicarbonate, 1.2 mMMgCl2,
and 1.2 mM CaCl2 (pH 7.4). ENaC sodium channels were inhibited with
100 mMamiloride (MacVinish et al., 1997); non-CFTR chloride channels were in-
hibitedwith250mMDNDS;CFTRcurrentswere stimulatedusing20mMforskolin
and 500 mM IBMX (Sigma) and inhibited using 5 mM CFTRinh-172 (provided by
CFFT courtesy of Dr. R. Bridges) (Pedemonte et al., 2005). Data were recorded
and analyzed using Labview (HSC). A paired t test was performed to compare
vehicle-treated and peptide-treated samples using GraphPad Prism software.
Flow Cytometry
BHK-deltaF508-3HA were grown to a density of 106 cells/ml and treated with
1 mMpeptides for 3 hr at 37C. To detect the total amount of CFTR reaching the
cell surface within the 3 hr incubation period, anti-HA antibody (1/1000) and
secondary goat-anti-mouse AlexaFluor647 (1/1000) were incubated with the
cells during peptide treatment (Haggie et al., 2006; Jin et al., 2007; Watson
et al., 2004). AlexaFluor647 signal was detected using the BD Aria Cell Sorter
or LSR II analyzer (lex = 650 nm; lem = 668 nm). Data were analyzed using
FlowJo 8.5 software. ANOVA statistical analysis was performed using Graph-
Pad Prism software.
Monitoring N-glycan Status
BHK-deltaF508-3HAwere grown to70%, confluency and treatedwith 10 mM
peptide. Cells were lysed in a modified RIPA lysis buffer (50 mM Tris-Cl,
150 mM NaCl, 1 mM EDTA, 0.1% SDS, 1% Triton X-100, Compete Mini
EDTA-free protease inhibitor tablet [Roche]). Protein concentration was deter-
mined by Lowry protein assaymethod and40 mg total protein was loaded per
sample and separated on SDS-PAGE (6% SDS-polyacrylamide gel). M3A7
(1/1000), goat-anti-mouse (1/1000) antibodies, and an ECL detection kit
(Amersham) were used to detect CFTR. An unpaired t test was used to deter-
mine significance of glycan processing in treated samples.Ltd All rights reserved
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BHK cells stably expressing deltaF508-CFTR were preincubated with 10 mM
CPP-CF-RXR or an equal volume of the vehicle control for 2 hr at 37C. Meta-
bolic labeling assays were performed as previously described (Lukacs et al.,
1994) with the following modifications. Cells were serum starved in DMEM
media containing 1 mM peptide or an equal volume of the vehicle (phos-
phate-buffered saline [PBS]) but lacking methionine and cysteine. Cells were
pulsed for 15 min with 150 mCi/ml 35S-methionine + 35S-cysteine labeling
mix (Perkin-Elmer). Cells were subsequently washed and chased in media
supplemented with 1 mM methionine, 1 mM cysteine, 2 mM glutamine, and
10% FBS in the presence of 1 mM CPP-CF-RXR or an equal volume of vehicle
(PBS) for 0–3 hr. This protocol was developed to maintain total peptide expo-
sure during the entire pulse-chase experiment at levels comparable to other
biochemical experiments. At each time point, cells were harvested in RIPA
lysis buffer and CFTR was immunoprecipitated using L12B4 antibody (Chem-
icon). Samples were analyzed by SDS-PAGE and amount of radioactively
labeled CFTR quantitated using Phosphorimager software (GE Healthcare,
Piscataway, NJ).
Confocal Microscopy
BHK-deltaF508-3HA were treated with AlexaFluor488 tagged CPP (1 mM) for
60 min at 37C to evaluate peptide uptake. Plasma membrane was labeled
with 10 mg/ml concanavalin A-Rhd (Molecular Probes). Images were acquired
under live cell conditions using the Zeiss Axiovert 200 inverted fluorescence
microscope equipped with a META emission scan head (63X magnification)
and analyzed on Volocity software (AlexaFluor488: lex = 495 nm, lem
519 nm; Rhd: lex = 530 nm, lem = 555 nm).
Statistical Analyses
In all comparative studies of multiple groups, one-way ANOVA was performed
with secondary analyses of all pairs using the Bonferroni test for significant
differences (unless otherwise stated). A single asterisk (*) denotes p < 0.05,
** denotes p < 0.01, and *** denotes (p < 0.001). In comparison of two groups,
the unpaired t test or paired t test was employed as appropriate. Prism soft-
ware (Version 4) was employed to conduct these tests (GraphPad software,
San Diego, CA).
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